UBS Group
CODX

UBS Group’s Co-Diagnostics CODX Stock Holding History

UBS Group’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-333
Closed -$194K – 8034
2020
Q2 		$194K Buy
+333
New +$152K ﹤0.01% 4814

Other funds holding CODX

PAG
Private Advisory Group Redmond, Washington $1.52B AUM 41.01% 1-Year Est. Return
SAM
Smartleaf Asset Management Boston, Massachusetts $2.77B AUM 22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
HWA
Heritage Wealth Advisors Richmond, Virginia $2.56B AUM 19.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

UBS Group's CODX Position: Q1 2026 in Review

UBS Group increased its Co-Diagnostics (CODX) stake by 603% in Q1 2026, buying an estimated $21.6K and bringing the position to 7,368 shares worth $13.7K. The position accounts for ﹤0.01% of the portfolio, ranked #8205.

UBS Group first reported a position in CODX in Q4 2017 and has held it in 32 quarters since. The position peaked at $440K in Q2 2020. 14 funds tracked by Wall St. Rank hold CODX as of Q1 2026.

  • UBS Group held 7,368 shares of Co-Diagnostics worth $13.7K as of Q1 2026.
  • UBS Group bought 6,320 Co-Diagnostics shares in Q1 2026, an estimated $21.6K.
  • Co-Diagnostics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8205 holding.
  • UBS Group first reported a position in Co-Diagnostics in Q4 2017 and has held it in 32 quarters since.
  • UBS Group's Co-Diagnostics position peaked at $440K in Q2 2020.
  • 14 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.